PFE - Arvinas Pfizer Plan To Broaden Development Of Breast Cancer Candidate | Benzinga
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with palbociclib (IBRANCE).
Interim results from the Phase 1b combination cohort demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer.
A clinical benefit rate (CBR) ...